New research validates a remote olfactory assessment that successfully identifies cognitive impairment and may provide a cost-effective screening tool for preclinical Alzheimer's disease and other neurodegenerative disorders.
The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Higher total fish consumption was associated with a reduced risk of multiple sclerosis disability progression, with a hazard ratio of 0.66 for confirmed disability worsening, researchers found.
Study reveals CADM patients face twice the misdiagnosis rate of DM patients, with diagnostic delays associated with increased hospitalization and ILD risks.